AbobotulinumtoxinA Treatment of Glabellar Lines Using a New Reconstitution and Injection Volume: Randomized, Placebo-Controlled Data

September 2021 | Volume 20 | Issue 9 | Original Article | 988 | Copyright © September 2021

Published online August 27, 2021

Joel Schlessinger MDa, Daniel P. Friedmann MDb, Flor Mayoral MDc, Deanne Mraz Robinson MDd, DeeAnna Glaser MDe, Douglas Wu MDf, Keith Marcus MDg, Michael Somenek MDh, Xiaoming Lin RN MSi

aSkin Specialists, Omaha, NE
bWestlake Dermatology Clinical Research Center, Austin, TX
cFlor Mayoral, MD, Coral Gables, FL
dModern Dermatology, Westport, CT
eSaint Louis University, St. Louis, MO
fDermatology Cosmetic Laser Medical Associates of La Jolla, San Diego, CA
gMarcus Facial Plastic Surgery, Redondo Beach, CA
hAdvanced Plastic Surgery, Washington, D.C.
iGalderma Laboratories, Fort Worth, TX

satisfied with their appearance, ≥78% felt more attractive, ≥77% felt better about themselves, ≥68% felt the treatment brought them a less tired look, and ≥60% a more youthful appearance, and almost all subjects in the aboBoNT-A group (≥98%) considered their treatment results to look natural (Figure 6).

A majority of subjects (73%) felt that they looked younger than their age, 1 month after treatment.

At month 6, 99% of subjects treated with aboBoNT-A responded that they would recommend this treatment to family and 96% that they would like to receive the same treatment again.

Subject-reported FACE-Q Scales
The subject-reported FACE-Q Appraisal of Lines Between the Eyebrows total score increased after treatment with aboBoNT-A, indicating that subjects were less bothered by their GL appearance post-treatment. Mean scores remained higher for aboBoNT-A than placebo from month 1 to month 6, with a peak at month 1 (Figure 7).

In the FACE-Q Psychological Function assessments, measuring concepts such as feeling happiness, confidence, and selfacceptance, the mean total scores showed an improvement in overall subject well-being in the aboBoNT-A group after treatment compared to placebo. Mean scores in the aboBoNT-A group improved after treatment (+9.1 at month 1) and remained higher than baseline throughout the study (+5.5 at month 6). Meanwhile, in the placebo group, there was a consistent decrease in the mean score after treatment (-1.2 at month 1; -3.5 at month 6 compared to baseline).